Dear Doctor Letter (Rote-Hand-Brief) on Thelin® (sitaxentan): Withdrawal from the market
2010.12.27
Active substance: sitaxentan
Withdrawal of Thelin® (sitaxentan) from the market due to unpredictable progression of serious hepatic impairment.
Risk information from 2010.12.14
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN